Welcome to Ignite Biomedical

Journey Towards better health

Prioritizing patient outcomes over product development. Our approach is centered on delivering precise, tailored solutions that address the unique challenges faced by individual patients.

Our mission

Our commitment is to deliver transformative solutions that not only advance medical science but also create tangible, positive impacts on individual lives and the broader healthcare ecosystem.

Our vision

Our vision is to pioneer a new era of personalized healthcare by addressing the critical unmet need for superior, objective decision support tools while transforming the landscape of medical decision-making, ultimately leading to a healthcare system that delivers more precise, effective, and personalized care for all patients.

Company Timeline

2022

Ignite Biomedical established with the primary goal of eliminating inefficient healthcare spending related to medication use. Our goal is to ensure the right patient receives the right medication at the right time, while reducing waste and optimizing clinical outcomes.

One of the many Inspirations behind our company formation

2023

• Pre-seed funding round closed, raising $1.5 million to use for discovery and development.

• Established a partnership with Liquid Biosciences to discover novel biomarkers for autoimmune diseases.

These diseases include:
• Inflammatory Bowel Disease
• Rheumatoid Arthritis
• Crohn's Disease
• Psoriatic Arthritis
• Plaque Psoriasis
‍
• Initiate partnership with SmartHealth Diagnostics for expertise and access to key laboratory services that dramatically speed up develop time and begin assay and test discovery and development.

2024

• Successfully completed the analytical validation of its Tumor Necrosis Factor-alpha Inhibitor (TNFi) Treatment Response Predictor (TRP). This milestone demonstrates the test's exceptional performance across critical parameters, including precision, repeatability, linearity, sensitivity, stability, and robustness.

• With a new company valuation, we began our second funding round for Clinical Validation and further developments.
‍

Read the latest press release

“What an incredible milestone we have achieved! The successful analytical validation of our TNF-alpha Inhibitor Treatment Response Predictor not only confirms the accuracy of our test but also underscores its potential impact on patient care. We are thrilled to advance towards clinical validation, as this step will bring us closer to transforming treatment outcomes for patients with inflammatory bowel disease and beyond.”

Claudio Faria,
Co-founder and CEO of Ignite Biomedical

2025-2026
Pipeline

Begin Clinical Validity phase:
‍
• 19-12 month period

• 900 patients with inflammatory disease

• Partnership with SmartHealth Diagnostics and a large clinical research organization (CRO)

• Aim to obtain Clinical Laboratory Improvement Amendment (CLIA) certification

Pre-Launch Activities

• Conduct clinical utility study

• Test portfolio with Palmetto MolDX program
• Negotiate pricing with Centers for Medicare & Medicaid Services (CMS)
•Meet with managed care and health system executives
• Commence general marketing and sales (primarily to Medicare patients)

Projects Overview:

• IGNB-001A IBD TNFI Precision Blood Test
(Analytically Validated)

• IGNB-001B RA TNFI Precision Blood Test
(In Discovery)

• IGNB-001C PSA/PSO TNFI Precision Blood Test
(In Discovery)

• IGNB-002 IBD Diagnostic and Prognostic Blood Test
(Discovery Complete)

• IGNB-003 IBD Next-Gen a4B7 Precision Blood Test
(Discovery Complete)

• IGNB-101 Substance Use Disorder Diagnostic (Discovery Complete)

Let's make a change!